麗珠醫藥(01513.HK)董事會審議通過麗珠生物增資議案
格隆匯1月18日丨麗珠醫藥(01513.HK)公吿,於2021年1月18日,公司董事會會議審議通過《關於珠海市麗珠生物醫藥科技有限公司增資的議案》,同意公司就公司與YF Pharmab Limited(以下簡稱“YF”)增資珠海市麗珠生物醫藥科技有限公司事宜與健康元藥業集團股份有限公司、YF、海南麗生聚源投資合夥企業(有限合夥)及其它相關方簽署《關於珠海市麗珠生物醫藥科技有限公司的增資擴股協議》。
審議通過《關於珠海市麗珠單抗生物技術有限公司股權轉讓的議案》,同意麗珠生物就受讓珠海市麗珠單抗生物技術有限公司100%股權事宜與麗珠生物科技香港有限公司簽署《關於珠海市麗珠單抗生物技術有限公司的股權轉讓協議》。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.